The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics
Open accessAbstract
Hepatocellular carcinoma (HCC) is a common malignancy in developing countries and its incidence is on the rise in the developing world. The epidemiology of this cancer is unique since its risk factors, including hepatitis C and B, have been clearly established. The current trends in the shifting incidence of HCC in different regions of the world can be explained partly by the changing prevalence of hepatitis. Early detection offers the only hope for curative treatment for patients with HCC, hence effective screening strategies for high-risk patients is of utmost importance. Liver transplantation and surgical resection remains the cornerstone of curative treatment. But major advances in locoregional therapies and molecular-targeted therapies for the treatment of advanced HCC have occurred recently. In this review, current trends in the worldwide epidemiology, surveillance, diagnosis, standard treatments, and the emerging therapies for HCC are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · cited 1×
“Hepatic Medicine: Evidence and Research 2012:4 Pacific trials) in patients with Child–Pugh class A cirrhosis and advanced HCC compatible with stage C by the BCLC system.(144,145) Single agent sorafenib for advanced HCC provided a modest benefit with a median improvement in overall survival for sorafenib over placebo o…”
MethodSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Cited by
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Park, J., Chen, M., Colombo, M., Roberts, L. R., Schwartz, M., Chen, P., Kudo, M., Johnson, P., Wagner, S., Orsini, L. S., et al. (2015) · Liver International · doi:10.1111/liv.12818 · Cited by 1,245
Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications
Wong, C.-M., Tsang, F. H.-C., & Ng, I. O.-L. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.169 · Cited by 424
Wang, F., Ying, H.-Q., He, B.-S., Pan, Y.-Q., Deng, Q.-W., Sun, H.-L., Chen, J., Liu, X., & Wang, S.-K. (2015) · Oncotarget · doi:10.18632/oncotarget.3219 · Cited by 348
Shang, X., Li, G., Liu, H., Li, T., Liu, J., Zhao, Q., & Wang, C. (2016) · Medicine · doi:10.1097/md.0000000000003811 · Cited by 330
Figarola, J. L., Singhal, J., Tompkins, J. D., Rogers, G. W., Warden, C., Horne, D., Riggs, A. D., Awasthi, S., & Singhal, S. S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.686352 · Cited by 41
Zhuang, Q., Zhou, T., He, C., Zhang, S., Qiu, Y., Luo, B., Zhao, R., Liu, H., Lin, Y., & Lin, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0341-z · Cited by 38
Shneor, D., Folberg, R., Pe'er, J., Honigman, A., & Frenkel, S. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2016.68 · Cited by 16
Metadata
- Authors
- Cabrera, R.
- Venue
- Hepatic Medicine: Evidence and Research
- Publisher
- Informa UK Limited
- Published
- 2012-05
- Volume
- 4
- Pages
- 19
- ISSN
- 1179-1535 (ISSN-L)
- OpenAlex
- W2015772717
- Cited by
- 274
- References
- 134
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.